AttendMe Owl Logo
AttendMe
Evidence Evolution
NeurologyNeurology

How This Evidence Evolved

Alzheimer's Disease-Modifying Therapy

The amyloid hypothesis tested

14.1

Timeline

Signal

Early observations and pilot data that first suggested a new direction

Amyloid target engagement and clinical benefit are distinct outcomes. In EMERGE/ENGAGE, aducanumab reduced amyloid markers in both studies, but high-dose treatment met the primary CDR-SB endpoint in EMERGE (difference −0.39; P=.012) and not ENGAGE (difference 0.03; P=.833). Both trials stopped after a pooled futility analysis; later analyses used more data. These discordant findings illustrate why plaque reduction alone cannot establish consistent clinical benefit.
Proof

Landmark RCTs and pivotal trials that established the evidence base

Aducanumab produced inconsistent results across EMERGE and ENGAGE: high-dose treatment met the CDR-SB endpoint in EMERGE but not ENGAGE. In CLARITY AD, CDR-SB increased by 1.21 with lecanemab and 1.66 with placebo at 18 months (difference -0.45). In TRAILBLAZER-ALZ 2, low/medium-tau participants had iADRS changes of -6.02 with donanemab and -9.27 with placebo at 76 weeks. These trials show less decline on specific measures in early disease, alongside important adverse effects.
Lecanemab appropriate use recommendations

For lecanemab, obtain a screening MRI within 12 months of initiation and use MRI to monitor ARIA. APOE4 carriers, especially homozygotes, have higher ARIA risk; recommend genotyping to inform risk discussions.

Guidelines

Integration into clinical practice guidelines and recommendations

A 2024 review reports lecanemab’s full FDA approval in July 2023 and similar approval for donanemab in July 2024. The 2023 lecanemab AUR recommends trial-like early AD, confirmed amyloid by PET/CSF, APOE genotyping for ARIA-risk discussions, screening MRI and monitoring. It did not establish benefit or safety in preclinical or more advanced disease. The review describes limited Medicare coverage for lecanemab; CMS eligibility remains a separate policy question.
Appropriate Use Recommendations

Lecanemab for early AD with confirmed amyloid; screening MRI and ARIA monitoring required.

Now

Current standard of care and ongoing research directions

CLARITY AD found a CDR-SB difference of −0.45 at 18 months with lecanemab versus placebo. TRAILBLAZER-ALZ 2 found an iADRS difference of 3.25 at 76 weeks in its low/medium-tau population. These measures and populations differ. ARIA can include edema and hemorrhagic changes; serious or fatal events can occur. Earlier intervention, tau-combination approaches and blood-based biomarkers raise research questions; the 2023 AUR considered blood biomarkers inadequate then for treatment selection.

Landmark Trials in This Story

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Frequently Asked Questions

Is there finally a treatment that slows Alzheimer's disease?+
Yes. CLARITY AD found less CDR-SB worsening at 18 months: 1.21 with lecanemab versus 1.66 with placebo (difference -0.45). In TRAILBLAZER-ALZ 2, iADRS changed by -6.02 with donanemab versus -9.27 with placebo in the low/medium-tau population at 76 weeks. Benefits require consideration alongside treatment risks.
What is ARIA and why does it matter?+
ARIA with edema or effusions occurred in 12.6% of lecanemab recipients and 24.0% of donanemab recipients in their respective trials. Most lecanemab ARIA is asymptomatic, but serious and very rarely fatal cases occur. APOE4 carriers, especially homozygotes, have higher ARIA risk with lecanemab. Lecanemab recommendations require a screening MRI and MRI monitoring for ARIA.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026